Bioblast Pharma (ORPN) Getting Somewhat Favorable News Coverage, Study Finds

Media coverage about Bioblast Pharma (NASDAQ:ORPN) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Bioblast Pharma earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.270760825623 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Separately, ValuEngine upgraded shares of Bioblast Pharma from a “strong sell” rating to a “sell” rating in a research report on Tuesday, September 26th.

Bioblast Pharma (NASDAQ:ORPN) opened at $2.40 on Tuesday. Bioblast Pharma has a 1 year low of $1.49 and a 1 year high of $7.75. The stock has a market cap of $8.02, a price-to-earnings ratio of -0.93 and a beta of -0.05.

TRADEMARK VIOLATION WARNING: “Bioblast Pharma (ORPN) Getting Somewhat Favorable News Coverage, Study Finds” was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright legislation. The original version of this story can be accessed at https://www.com-unik.info/2017/12/26/bioblast-pharma-orpn-getting-somewhat-favorable-news-coverage-study-finds.html.

Bioblast Pharma Company Profile

Bioblast Pharma Ltd (BioBlast) is an Israel-based development-stage biopharmaceutical company. The Company is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. It focuses on therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease.

Insider Buying and Selling by Quarter for Bioblast Pharma (NASDAQ:ORPN)

Receive News & Ratings for Bioblast Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioblast Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit